The MHRA has published a new blog and guidance
Date: 24 November 2020
Guidance on minimising disruptions to the conduct and integrity of clinical trials of medicines during COVID-19
Actions that trial sponsors should consider to build resilience into clinical trial design. The research management working group of the Forum was pleased to provide early feedback to inform this guidance, welcoming Expert GCP Inspector Gail Francis to a group meeting for discussion on deviations and monitoring.